Cardiovascular events after polychemotherapy of multiple myeloma: modern ways to diagnostics

Abstract

Heart dysfunction that occurred after using cytostatic drugs and monoclonal antibodies may be a limit factor in the treatment of multiple myeloma. Side effects of chemotherapy include hypotension, hypertension, arrhythmias, conduction disturbances, pericarditis, thromboembolic events, heart failure, death. The risk of cardiotoxicity may be increased by some factors that include drug exposure, age, history of heart diseases, arterial hypertension, drug combination, previous radiotherapy or chemotherapy. It’s important to detect cardiovascular toxicity before the appearance of clinical signs of heart and vessel disturbance. The role of markers in the elicitation of risk groups of cardiovascular events is uncertain yet. Early diagnostics and definition of prognostic factors of cardiovascular toxicity appeared after polychemotherapy of oncohematological diseases are important and not solve problems.

Keywords

• multiple myeloma
• cardiovascular events
• chemotherapy
• diagnostics
• prognostic factors